Table 3.

Plasma pharmacokinetics of sorafenib (400 mg twice daily) and gefitinib (250 mg) when given as single agents or after coadministration (geometric mean)

Sorafenib
Sorafenib run-in (n = 8), meanSorafenib plus gefitinib, cycle 1 (n = 4), meanSorafenib plus gefitinib, cycle 1/sorafenib run-in
LS mean ratio90% CI (P)
Cmax (mg/L)4.64.61.000.83-1.21 (0.9973)
AUC0-12 (mg h/L)31.330.70.980.81-1.19 (0.8496)
Gefinitib
Gefitinib run-in (n = 12), meanGefitinib plus sorafenib, Cycle 1 (n = 8), meanSorafenib plus gefitinib, cycle 1/gefitinib run-in



LS mean ratio
90% CI (P)
Cmax (mg/L)432.7321.90.740.63-0.88 (0.0131)
AUC0-24 (mg h/L)8,080.25,049.70.620.51-0.77 (0.0035)
  • Abbreviations: 95% CI, 95% confidence interval; LS, least squares.